Level D· Scientific groundwork from lab and animal studiesNarrative ReviewEurope PMCOpen access

A bibliometric analysis of research trends in mesenchymal stem cell therapy for neonatal bronchopulmonary dysplasia: 2004-2024

Bai L., Xin Y.

Narrative Review on Chronic Inflammation, Immune Modulation, published in Front Pediatr (2025) — summary generated from the PubMed abstract.

Open my reading list
Level D· Scientific groundwork from lab and animal studiesEvidence level of this study

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Narrative Review
Journal
Front Pediatr (2025)
Reported sample size
—
Source database
Europe PMC
PMID
40530182
PMCID
PMC12172653
DOI
10.3389/fped.2025.1558301
Citations
1

Abstract (original English)

Introduction Bronchopulmonary dysplasia (BPD) is a chronic lung disease predominantly affecting preterm infants, often requiring mechanical ventilation and supplemental oxygen. The pathogenesis of BPD involves a combination of genetic susceptibility and environmental insults, such as oxidative stress and mechanical ventilation. Mesenchymal stem cells (MSCs) have emerged as a promising therapeutic option for BPD due to their immunomodulatory, anti-inflammatory, and regenerative properties. This study aims to perform a bibliometric analysis of the publication landscape surrounding MSC therapy for BPD to identify research trends, collaborative networks, influential research clusters, and emerging research frontiers from 2004 to 2024. Methods A bibliometric analysis was conducted using the Web of Science Core Collection (WoSCC) as the primary database due to its comprehensive citation indexing and standardized metadata. To ensure data integrity, we included publications from January 2004 (when the first relevant MSC studies for BPD began appearing) to November 2024. The search query combined terms related to BPD and MSCs, focusing on English-language articles and reviews. After retrieval, data were cleaned through duplicate removal and relevance verification processes. Quantitative analysis was performed on publication counts, authors, journals, institutions, and countries. Visual

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.
  • • This is a narrative review: it collects no new patient data and does not systematically appraise evidence quality.

Evidence level

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

How we grade evidence

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research